Recent Analysts’ Ratings Changes for Veeva Systems (VEEV)

Veeva Systems (NYSE: VEEV) has recently received a number of price target changes and ratings updates:

• 6/4/2026 – Veeva Systems had its “outperform” rating reaffirmed by BNP Paribas Exane. They now have a $285.00 price target on the stock.
• 6/4/2026 – Veeva Systems had its “buy” rating reaffirmed by TD Cowen.
• 6/4/2026 – Veeva Systems had its price target lowered by Mizuho from $295.00 to $270.00. They now have an “outperform” rating on the stock.
• 6/4/2026 – Veeva Systems had its price target raised by Wells Fargo & Company from $317.00 to $320.00. They now have an “overweight” rating on the stock.
• 6/4/2026 – Veeva Systems had its “outperform” rating reaffirmed by Evercore Inc. They now have a $185.00 price target on the stock.
• 6/4/2026 – Veeva Systems had its price target lowered by Stifel Nicolaus from $245.00 to $230.00. They now have a “buy” rating on the stock.
• 6/4/2026 – Veeva Systems had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $225.00 price target on the stock.
• 6/4/2026 – Veeva Systems had its price target raised by Citigroup Inc. from $176.00 to $190.00. They now have a “neutral” rating on the stock.
• 6/4/2026 – Veeva Systems had its price target lowered by The Goldman Sachs Group, Inc. from $190.00 to $165.00. They now have a “sell” rating on the stock.
• 6/4/2026 – Veeva Systems had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $225.00 price target on the stock.
• 6/4/2026 – Veeva Systems had its price target lowered by Canaccord Genuity Group Inc. from $235.00 to $220.00. They now have a “hold” rating on the stock.
• 6/4/2026 – Veeva Systems had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $275.00 price target on the stock.
• 6/4/2026 – Veeva Systems had its price target lowered by UBS Group AG from $220.00 to $190.00. They now have a “neutral” rating on the stock.
• 6/4/2026 – Veeva Systems had its price target lowered by BMO Capital Markets from $220.00 to $175.00. They now have a “market perform” rating on the stock.
• 6/4/2026 – Veeva Systems had its price target lowered by Barclays PLC from $250.00 to $235.00. They now have an “overweight” rating on the stock.
• 6/4/2026 – Veeva Systems had its price target raised by Robert W. Baird from $250.00 to $260.00. They now have an “outperform” rating on the stock.
• 6/4/2026 – Veeva Systems had its price target lowered by Piper Sandler from $285.00 to $235.00. They now have an “overweight” rating on the stock.
• 6/4/2026 – Veeva Systems had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $270.00 price target on the stock.
• 6/4/2026 – Veeva Systems had its “buy” rating reaffirmed by BTIG Research. They now have a $340.00 price target on the stock.
• 5/18/2026 – Veeva Systems had its price target lowered by Oppenheimer Holdings, Inc. from $275.00 to $225.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Veeva Systems was downgraded by Zacks Research from “strong-buy” to “hold”.
• 4/15/2026 – Veeva Systems was upgraded by Zacks Research from “hold” to “strong-buy”.

Insiders Place Their Bets

In other news, Director Priscilla Hung sold 750 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $155.64, for a total transaction of $116,730.00. Following the completion of the sale, the director owned 3,253 shares in the company, valued at approximately $506,296.92. This represents a 18.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by corporate insiders.

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.